NCT02298153View on ClinicalTrials.gov

A Study of Atezolizumab (MPDL3280A) in Combination With Epacadostat (INCB024360) in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial Carcinoma (ECHO-110)

PHASE1TerminatedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

November 8, 2017

Study Completion Date

November 8, 2017

Conditions
NSCLC (Non-small Cell Lung Carcinoma)UC (Urothelial Cancer)
Interventions
DRUG

atezolizumab

atezolizumab: administered intravenously (IV) every three weeks (q3w)

DRUG

epacadostat

epacadostat: Oral daily dosing

Trial Locations (6)

10065

Memorial Sloan Kettering Cancer Center, New York

85258

Pinnacle Oncology Hematology, Scottsdale

98109

University of Washington, Seattle

06510

Yale University, New Haven

02114

Harvard-Mass General Hospital, Boston

02215

Dana Farber Cancer Institute, Boston

Sponsors

Lead Sponsor

Incyte Corporation

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

collaborator

Genentech, Inc.

INDUSTRY

lead

Incyte Corporation

INDUSTRY